Sealantium Medical Ltd.   Report issue

For profit Phase 2
Founded: Rosh HaAyin Israel (2011)

Organization Overview

First Clinical Trial
2020
NCT04660721
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Sealantium Medical Ltd.

Active Ingredients

Drugs in Phase 2 Trials (3)

calcium chloride (1 trial)

fibrinogen (human) (RiaSTAP) (1 trial)

thrombin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hemorrhage (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 3